Floatz logo

FLUTRICICLAMIDE

Parkinson Disease

Aaron Ritter, MDSmall moleculePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

166 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Ropinirole
Titan Pharmaceuticals
Phase 4BBB
Benserazide
Ankara Ataturk Sanatorium Training and Research Hospital
Phase 4BBB
Ongentys
Bial - Portela C S.A.
Phase 4BBB
Ctc-501
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LEVODOPA
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

FLUTRICICLAMIDE is also rated in:

InflammationDormant
CCC
Indicative ·
53 / 100
View asset →
Alzheimer DiseaseDormant
CCC
Indicative ·
48 / 100
View asset →
amyotrophic lateral sclerosisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →